Guilin Sanjin Pharmaceutical Co., Ltd.
SZSE:002275.SZ
14.38 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,193.992 | 2,171.603 | 1,959.733 | 1,741.225 | 1,566.485 | 1,640.424 | 1,584.673 | 1,616.016 | 1,525.224 | 1,371.821 | 1,466.352 | 1,452.636 | 1,311.547 | 1,161.781 | 983.46 | 1,110.829 | 986.158 | 893.048 | 797.852 |
| Cost of Revenue
| 583.343 | 602.569 | 568.781 | 447.097 | 448.861 | 445.256 | 432.426 | 389.259 | 410.211 | 376.907 | 415.12 | 395.814 | 387.798 | 330.975 | 272.086 | 255.068 | 253.361 | 243.994 | 238.081 |
| Gross Profit
| 1,610.649 | 1,569.035 | 1,390.952 | 1,294.127 | 1,117.624 | 1,195.168 | 1,152.248 | 1,226.757 | 1,115.013 | 994.915 | 1,051.232 | 1,056.822 | 923.749 | 830.806 | 711.374 | 855.76 | 732.797 | 649.054 | 559.771 |
| Gross Profit Ratio
| 0.734 | 0.723 | 0.71 | 0.743 | 0.713 | 0.729 | 0.727 | 0.759 | 0.731 | 0.725 | 0.717 | 0.728 | 0.704 | 0.715 | 0.723 | 0.77 | 0.743 | 0.727 | 0.702 |
| Reseach & Development Expenses
| 173.292 | 158.062 | 217.036 | 202.45 | 154.282 | 104.112 | 64.666 | 53.883 | 37.591 | 31.026 | 22.195 | 12.847 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 46.752 | 68.857 | 62.589 | 41.462 | 39.184 | 31.183 | 29.416 | 33.935 | 25.754 | 24.163 | 22.862 | 39.283 | 39.249 | 35.458 | 29.034 | 88.982 | 76.959 | 76.708 | 72.038 |
| Selling & Marketing Expenses
| 593.853 | 717.857 | 538.344 | 564.953 | 497.476 | 498.241 | 452.627 | 497.972 | 491.395 | 443.553 | 418.036 | 462.928 | 411.274 | 369.401 | 299.08 | 375.503 | 306.242 | 265.479 | 246.615 |
| SG&A
| 640.605 | 896.459 | 600.933 | 606.415 | 536.66 | 529.424 | 482.043 | 531.908 | 517.15 | 467.715 | 440.897 | 502.211 | 450.523 | 404.858 | 328.114 | 464.485 | 383.201 | 342.187 | 318.653 |
| Other Expenses
| 151.979 | -9.053 | 164.581 | 75.285 | 90.696 | 94.942 | -2.572 | -1.675 | 13.134 | 17.426 | 7.838 | 29.235 | 7.799 | 2.436 | 3.838 | 7.439 | 0.908 | 9.432 | 0.784 |
| Operating Expenses
| 965.877 | 1,066.938 | 982.551 | 884.151 | 781.638 | 728.478 | 653.866 | 687.719 | 664.845 | 594.699 | 551.591 | 590.346 | 537.229 | 491.841 | 412.065 | 481.431 | 397.947 | 354.879 | 329.933 |
| Operating Income
| 644.773 | 518.263 | 446.781 | 429.035 | 354.739 | 469.416 | 498.258 | 564.66 | 467.342 | 423.007 | 523.435 | 484.623 | 398.578 | 362.709 | 312.848 | 369.952 | 326.726 | 289.177 | 230.47 |
| Operating Income Ratio
| 0.294 | 0.239 | 0.228 | 0.246 | 0.226 | 0.286 | 0.314 | 0.349 | 0.306 | 0.308 | 0.357 | 0.334 | 0.304 | 0.312 | 0.318 | 0.333 | 0.331 | 0.324 | 0.289 |
| Total Other Income Expenses Net
| -0.838 | 0.021 | -0.601 | 0.023 | -10.574 | -1.78 | -2.572 | -1.675 | 12.181 | 16.242 | 7.822 | 28.566 | 7.674 | 2.422 | 15.403 | 0.829 | -7.292 | 8.641 | 0.76 |
| Income Before Tax
| 643.935 | 518.284 | 446.18 | 429.058 | 344.165 | 467.636 | 495.686 | 562.985 | 479.566 | 440.303 | 531.198 | 513.212 | 406.306 | 365.145 | 316.637 | 377.391 | 327.559 | 297.818 | 231.23 |
| Income Before Tax Ratio
| 0.293 | 0.239 | 0.228 | 0.246 | 0.22 | 0.285 | 0.313 | 0.348 | 0.314 | 0.321 | 0.362 | 0.353 | 0.31 | 0.314 | 0.322 | 0.34 | 0.332 | 0.333 | 0.29 |
| Income Tax Expense
| 122.401 | 96.985 | 116.653 | 85.339 | 67.144 | 75.493 | 82.34 | 98.583 | 85.906 | 63.63 | 86.332 | 92.944 | 75.155 | 73.246 | 59.254 | 69.559 | 53.47 | 48.32 | 36.214 |
| Net Income
| 521.534 | 421.299 | 329.527 | 343.719 | 277.021 | 392.143 | 413.346 | 464.402 | 393.66 | 376.673 | 444.866 | 420.268 | 331.152 | 291.954 | 258.758 | 307.315 | 273.727 | 249.178 | 194.804 |
| Net Income Ratio
| 0.238 | 0.194 | 0.168 | 0.197 | 0.177 | 0.239 | 0.261 | 0.287 | 0.258 | 0.275 | 0.303 | 0.289 | 0.252 | 0.251 | 0.263 | 0.277 | 0.278 | 0.279 | 0.244 |
| EPS
| 0.89 | 0.72 | 0.56 | 0.6 | 0.48 | 0.67 | 0.7 | 0.79 | 0.67 | 0.64 | 0.75 | 0.71 | 0.56 | 0.49 | 0.44 | 0.55 | 0.52 | 0.47 | 0.37 |
| EPS Diluted
| 0.89 | 0.72 | 0.56 | 0.6 | 0.48 | 0.67 | 0.7 | 0.79 | 0.67 | 0.64 | 0.75 | 0.71 | 0.56 | 0.49 | 0.44 | 0.55 | 0.52 | 0.47 | 0.37 |
| EBITDA
| 767.861 | 660.85 | 590.795 | 561.021 | 443.237 | 564.012 | 604.186 | 633.453 | 550.051 | 508.069 | 571.602 | 546.949 | 438.319 | 392.03 | 343.359 | 390.475 | 358.658 | 317.901 | 250.643 |
| EBITDA Ratio
| 0.35 | 0.304 | 0.301 | 0.322 | 0.283 | 0.344 | 0.381 | 0.392 | 0.361 | 0.37 | 0.39 | 0.377 | 0.334 | 0.337 | 0.349 | 0.352 | 0.364 | 0.356 | 0.314 |